Bristol-Myers Squibb and ZymoGenetics to collaborate on hepatitis C compound Bristol-Myers Squibb and ZymoGenetics, Inc. Have announced a worldwide collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program more . Under the conditions of the collaboration, Bristol-Myers Squibb decided to pay ZymoGenetics an upfront money payment of $85 million for the development and commercialization rights to PEG-Interferon lambda, also to pay an additional license fee of $20 million in 2009 2009. ZymoGenetics could receive additional payments of up to $430 million based on pre-defined advancement and regulatory milestones for PEG-Interferon lambda in Hepatitis C, up to $287 million in advancement and regulatory milestones for other potential indications, and up to $285 million based on pre-defined sales-based milestones.
The European research also found that caesarean section delivery, infant prematurity, and maternal history of injection drug use were not connected with HCV transmission. The entire rate of transmission of the virus from infected mother to child was 6.2 % in the European study and 3.6 % in the U.S. Research. Our results strongly claim that women should not be offered an elective caesarean section or discouraged from breastfeeding based on hepatitis C infection by itself, said Pier-Angelo Tovo, MD, the lead author of the European study.S. Authors. In an accompanying editorial, R. Palmer Beasley, MD, of the University of Texas at Houston, emphasized the European study’s novel obtaining of a gender difference in transmission rates and suggested that higher HCV rates in female newborns may be because of excess mortality in contaminated men in utero.